Cerebrolysin
Also known as: Cerebrolysin®
Neuropeptide Preparation | Neurological Recovery
Overview
Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.
Key benefits
- Direct brain delivery
- Standardized dosing
- Extensive clinical evidence
- Ready-to-use formulation
- Used clinically in 50+ countries
Mechanism of action
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.
Molecular data
- Type
- Purified porcine brain proteins
- Half-life
- Minutes (component-dependent; e.g., BDNF ~10 min)
Sequence
Bioactive peptide mixture
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cognitive
Neuroprotection
Recovery
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | Up to 10mL | Once daily | — |
| — | Up to 5mL | Once daily | — |
| — | 20-50mL | Once daily for 10-21 days | — |
| — | 20-50mL | Once daily for 7-30 days | — |
| — | 10-30mL | 5 days weekly for 4 weeks | — |
| — | 10-30mL | 5 days weekly for 4 weeks | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well tolerated
- Possible mild dizziness or agitation in early treatment
Contraindications
- Epilepsy
- Severe renal insufficiency
- History of severe allergic reactions to porcine products
Monitoring
- Monitor for allergic reactions during first dose
- Renal function in patients with kidney disease
- Seizure activity in at-risk patients
- Cardiovascular status during administration
References
Primary literature and clinical-trial data informing this entry.